Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.
The approval of dupilumab (Dupixent, Sanofi Regeneron) for moderate-to-severe atopic dermatitis adds a much-needed option that may alter the broader course of atopic disease, experts told Dermatology Times.
Atopic dermatitis (AD) is one of the most common skin conditions treated by dermatologists. As such, articles on atopic dermatitis tend to be some of the most popular Dermatology Times content. These are the top three AD articles.
When it comes to treating atopic dermatitis in non-white racial ethnic groups, there are variations in prevalence, genetic factors and clinical presentation.
Atopic dermatitis normalizes the skin micro biome. Anti-inflammatory medications for atopic dermatitis reduce colonization. Children with atopic dermatitis more prone to molluscum infection.
Emerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.
A recent study looked at the inpatient burden on patients with atopic dermatitis (AD) in the United States and found a significant financial burden due to the high hospitalization rates.
Drugs to treat atopic dermatitis are at the top of the FDA’s dermatology list. Biologics and PDE4 inhibitors show promise in the treatment of AD. Approval is still needed for the use of biologics to treat AD in pediatric patients.
The April Table of the Month discusses diagnostic and therapeutic tips for AD patients.
Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
A new research center makes a database of five million human pathology specimens and 22,000 living consented patients, all searchable by diagnoses, as well as cutting edge human analytic techniques available to anyone interested in carrying out translational skin disease research on human cells and tissues.
Promising new treatments recently approved or under development for atopic dermatitis include crisaborole, JAK inhibitors and dupilumab, an expert said.
Experts weigh in on what to know about the new addendum to the peanut allergy prevention guidelines.
The FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.
Research aimed at understanding the host-microbial interface in atopic dermatitis is ongoing but already providing insights for novel therapeutic strategies.
This year has seen many advancements in pediatric dermatologic care spanning inflammatory conditions to skin cancer as well as the nuances of these conditions in skin of color patients. These are the top 5 pediatric articles of 2016 from Dermatology Times.
Exciting research is likely to change treatment for children. Dr. Eichenfield discusses advancements in treating this population.
New data suggests positive safety and efficacy profile. Further studies need to assess long-term use.
Direct sequencing data, together with culture data, supplies researchers with information about communities of bacteria and fungi on the skin.
A new study using crowdsourcing harnesses the power of social media chatter to better understand unmet needs in eczema research.
Microbial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.
Pediatric atopic dermatitis and acne have some similarities when these present in skin of color and lighter-skin children. But there are important differences when these common skin conditions affect darker skin types. An expert discusses how treatments should be approached.
There’s a lot of blame to go around when it comes to why drug costs are rising in dermatology. We’ll let the research do the finger pointing.
Part of the management of contact dermatitis is identifying the offending agent through patch testing and eliminating contact with the offending agent.
UK-based Ziarco Pharma Ltd. recently announced positive phase 2a results for ZPL-389, a once daily oral histamine H4 receptor antagonist, for the treatment of moderate to severe atopic dermatitis.
